New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:09 EDTLLYEli Lilly acquires all development rights for calcitonin peptide antibody
Eli Lilly and Company announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide, or CGRP, antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two processes that have been implicated in migraine headaches. This novel molecule was discovered by Lilly scientists and then licensed to Arteaus Therapeutics for development in the clinical proof-of-concept study. Financial terms of the deal were not disclosed.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
August 20, 2015
13:26 EDTLLYOn The Fly: Top stock stories at midday
Subscribe for More Information
11:33 EDTLLYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTLLYEli Lilly's Jardiance for diabetes meets primary endpoint in clinical trial
Subscribe for More Information
August 18, 2015
10:01 EDTLLYEli Lilly says Humalog 200 units/mL KwikPen available in U.S. pharmacies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use